Spherix Global Insights Launches Market Dynamix™: PD-1 Inhibition in Solid Tumors, Delivering a Comprehensive Assessment of Biosimilar and Subcutaneous PD-1 Market Dynamics Across Key Oncology Indications

Core Insights - Spherix Global Insights has launched its Market Dynamix™ service focusing on PD-1 Inhibition in Solid Tumors, providing analysis and advisory services for the immuno-oncology landscape as new PD-1 biosimilars and subcutaneous formulations approach market entry [1][2] Study Focus and Methodology - The 2025 edition of Market Dynamix™ will integrate quantitative insights from 100 U.S.-based oncologists, assessing current treatment algorithms and future expectations regarding the PD-1 inhibitor class [3] - The study will evaluate the impact of biosimilars and subcutaneous delivery formats on manufacturers, providers, and payers, delivering actionable intelligence for commercial planning and competitive positioning [3] - In 2026, the tracking will expand with RealTime Dynamix™: PD-1 Inhibition in Solid Tumors, providing quarterly updates on prescriber perceptions and competitive dynamics [3] Market Dynamics - The study will explore oncologist familiarity and perceived clinical equivalence of biosimilar PD-1 inhibitors, as well as adoption intent and expected impacts on practice economics and patient access [6] - It will also assess attitudes toward subcutaneous PD-1 formulations, focusing on convenience and anticipated shifts in site-of-care dynamics [6] - The analysis will include forecasts for PD-1 brand positioning and market share over the next 12 months, along with the influence of biomarker testing on treatment selection [6]